• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Elevance’s Data Partnership And Cancer Care Model Results Require Action From Elevance Health (ELV) Investors?

    Simply Wall St·08/13/2026 15:27:32
    Listen to the news
    • In late July 2026, Carelon Research, a subsidiary of Elevance Health, announced a partnership with Manifold to give life sciences researchers secure, scalable access to Elevance’s real-world data alongside third-party datasets without moving information outside their organizations.
    • A few days earlier, Elevance Health reported that its enhanced connected cancer care model, including Cancer Care Engagement and Oncology Provider Enablement Clinicians, was associated with fewer avoidable hospitalizations and more coordinated, patient-centered oncology support.
    • We’ll now examine how Elevance’s data partnership and analytics-driven cancer care enhancements may influence the company’s broader investment narrative.

    Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

    Elevance Health Investment Narrative Recap

    To own Elevance Health, you generally need to believe its push into data driven care and diversified services can offset pressure from medical costs and regulation. The latest cancer care and data announcements reinforce the core catalyst of analytics and value based care potentially improving cost predictability, but they do not fundamentally change the near term risk that elevated ACA and Medicaid medical trends and delayed rate recovery could still weigh on margins.

    The enhanced Cancer Care Engagement program is most relevant here, because it directly ties analytics to measurable reductions in avoidable admissions and readmissions. For investors focused on Elevance’s cost trend risk, these reported outcomes make the value based care and Carelon narratives more concrete, while also highlighting execution risk if similar analytics driven programs are scaled across more complex, higher cost populations.

    Yet even as these programs expand, one risk investors should be aware of is how prolonged, elevated medical cost trends could still...

    Read the full narrative on Elevance Health (it's free!)

    Elevance Health’s narrative projects $209.8 billion revenue and $7.3 billion earnings by 2029. This requires 1.4% yearly revenue growth and a $2.3 billion earnings increase from $5.0 billion today.

    Uncover how Elevance Health's forecasts yield a $449.10 fair value, a 13% upside to its current price.

    Exploring Other Perspectives

    ELV 1-Year Stock Price Chart
    ELV 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming Elevance could reach about US$214.8 billion in revenue and US$7.3 billion in earnings by 2029, but this bullish view sits alongside concerns about ongoing elevated medical costs. As the new data partnerships and cancer care analytics roll out, you might find that both the upside case and the risk of margin pressure look very different from what these pre news forecasts implied.

    Explore 6 other fair value estimates on Elevance Health - why the stock might be worth over 3x more than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Elevance Health research is our analysis highlighting 4 key rewards that could impact your investment decision.
    • Our free Elevance Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Elevance Health's overall financial health at a glance.

    Seeking Other Investments?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.